The Challenge: Gaining Competitive Intelligence on upcoming generics competitors in the EU oncology (breast cancer) space.
LucidQuest worked closely with a large-cap Pharma company to support them with crucial intelligence on upcoming Gx competitors in the EU oncology (breast cancer) space.
The Action: Secondary and primary intelligence interviewing multiple stakeholders for hyper-focused insights on competitors’ manufacturing and commercial capabilities.
LucidQuest conducted secondary and primary intelligence over three months, interviewing competitor company sources, regulatory agency staff across the EU, API manufacturers, and retail pharmacy staff to better understand Gx competitors’ launch capabilities and “reach” in EU markets and launch sequence.
The Result: With our insights, our client crafted a well-prepared defense against the Gx entrants
LucidQuest prepared a detailed report that included an up-to-date view of the leading Gx competitors’ capabilities to launch and distribute the Gx asset, as well as insights on their EU filing and launch dates and P&R plans.
Our client was able to use these insights to inform their local affiliates as they were preparing to defend against the Gx entrants.
#breastcancer #casestudy #CompetitiveIntelligence #EUgenerics #EUpharma #genericcancerdrugs #Oncology #ourwork #pharmamanufacturing #Lucidquest #HealthcareConsulting